Neda Fayyazi | Bioinformatics | Excellence in Innovation

Posted on by ScienceFather

Dr. Neda Fayyazi | Bioinformatics | Excellence in Innovation

ogen/ medical iincubator, Iran

 Author Profile 📚

Google Scholar

Early Academic Pursuits 🎓

Dr. Neda Fayyazi’s academic journey is marked by significant achievements, beginning with her Ph.D. in Pharmaceutical and Medicinal Chemistry from Isfahan University of Medical Sciences, which she completed between February 2015 and October 2019. Her outstanding academic performance earned her a top rank (A) with a GPA of 3.60. Dr. Fayyazi’s thesis, titled Molecular modeling, synthesis, and biological evaluation of hybrid multi-target iron chelators for anticancer and antimalarial applications, was highly regarded, securing an Excellent Rank (A). Her interdisciplinary focus on combining computational techniques and medicinal chemistry positions her as an emerging leader in the field.

Professional Endeavors 💼

Dr. Fayyazi’s professional experience spans academia and industry, with roles in pharmaceutical companies and research institutions. She has worked with leading organizations, including TPCO Holding, Pars Darou Pharmaceutical Company, and Barkat Holding. Her roles involved product development, technology transfer, and research in the areas of pharmaceutical formulations, softgel production, and drug discovery. As a board member of Ozhan Pharma Group and an active participant in various projects, Dr. Fayyazi continues to bridge the gap between scientific research and commercial application.

Contributions and Research Focus 🔬

Dr. Fayyazi’s research contributions are primarily in the field of Medicinal Chemistry, with a focus on drug design, molecular modeling, and hybrid molecule synthesis. Her work on molecular dynamics simulations and protein-ligand interactions using cutting-edge tools like Gromacs, GOLD, and Discovery Studio has been instrumental in advancing the understanding of drug interactions at the molecular level. Additionally, she is passionate about developing novel drug delivery systems, particularly in sustained-release formulations, and exploring natural products for therapeutic potential. Her research integrates AI and machine learning approaches in drug discovery, a testament to her forward-thinking methodology.

Impact and Influence 🌍

Dr. Fayyazi has had a significant impact on the pharmaceutical industry and academia through her work in drug discovery, technology transfer, and industry collaboration. Her expertise in bioassay-guided screening and cancer therapy research has led to breakthroughs in medicinal chemistry, especially in the development of multi-target anticancer agents. As a member of various prestigious associations such as the European Bioinformatics Association and the American Chemical Society, she has contributed to the global advancement of biotechnology and pharmaceutical sciences. Her work has garnered recognition, including a prize for innovative ideas in drug research at the Euro Chemistry Conference in Berlin (2019).

Academic Cites and Research Recognition 📑

Dr. Fayyazi’s academic publications and research outputs are highly cited in the fields of molecular modeling and pharmaceutical sciences. Her collaborations with research institutions and pharmaceutical companies have cemented her reputation as a thought leader in medicinal chemistry. Notably, her research on iron chelators and cancer treatment has positioned her as a pivotal figure in advancing drug discovery methodologies. Her work is frequently referenced in studies related to drug design, molecular dynamics, and natural product research.

Technical Skills and Expertise 🧑‍🔬

Dr. Fayyazi’s technical proficiency extends across a broad spectrum of advanced scientific methods and tools. She is highly skilled in QSAR (Quantitative Structure-Activity Relationship), molecular dynamics simulations, and protein-ligand interactions. Her ability to synthesize hybrid compounds, coupled with her expertise in computational chemistry and machine learning, allows her to investigate complex biochemical interactions and design novel therapeutic agents. Furthermore, her knowledge of Linux environments, scripting, and drug discovery processes in natural products underscores her broad technical competence.

Teaching Experience 📚

Dr. Fayyazi’s passion for teaching is evident in her role as an educator at Isfahan University of Medical Sciences, where she has taught undergraduate students in organic chemistry, pharmacology, and computational chemistry. She has also supervised and mentored numerous master’s and Ph.D. students in the fields of medicinal chemistry and bioassays. Her teaching methods emphasize interdisciplinary approaches, integrating cutting-edge technology and scientific research into practical applications.

Legacy and Future Contributions 🌟

Looking ahead, Dr. Fayyazi’s future contributions are poised to continue shaping the pharmaceutical and biotechnology sectors. Her ongoing projects in controlled release formulations, softgel technology transfer, and sustained-release drug delivery systems demonstrate her commitment to improving patient outcomes through innovative therapeutic solutions. As she works to bridge the gap between academic research and industry applications, Dr. Fayyazi aims to inspire the next generation of scientists and continue her impactful work in drug design and natural product research.

Honor and Awards 🏆

Dr. Fayyazi’s career has been punctuated with numerous accolades, including the Best Score in the National Entrance Exam for Pharmaceutical Projects in 2001, the Productivity Management Prize at Soha Pharmaceutical Company (2010), and the prestigious PhD Scholarship for Medicinal Chemistry at Isfahan University. These awards reflect her unwavering dedication to excellence and innovation in both academic and industrial settings.

 

Top Noted Publications 📖

Molecular dynamics simulation and 3D-pharmacophore analysis of new quinoline-based analogues with dual potential against EGFR and VEGFR-2
    • Authors: N. Fayyazi, A. Fassihi, S. Esmaeili, S. Taheri, J.B. Ghasemi, L. Saghaie
    • Journal: International Journal of Biological Macromolecules
    • Year: 2020
Pharmacophore modeling, synthesis, scaffold hopping and biological β-Hematin inhibition interaction studies for anti-malaria compounds
    • Authors: N. Fayyazi, S. Esmaeili, S. Taheri, F.F. Ribeiro, M.T. Scotti, L. Scotti, …
    • Journal: Current Topics in Medicinal Chemistry
    • Year: 2019
Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19
    • Authors: N. Fayyazi, T. Mostashari-Rad, J.B. Ghasemi, M.M. Ardakani, F. Kobarfard
    • Journal: Journal of Biomolecular Structure and Dynamics
    • Year: 2022
Design, synthesis, in silico studies, and antiproliferative evaluations of novel indolin-2-one derivatives containing 3-hydroxy-4-pyridinone fragment
    • Authors: P. Shirvani, N. Fayyazi, S. Van Belle, Z. Debyser, F. Christ, L. Saghaie, …
    • Journal: Bioorganic & Medicinal Chemistry Letters
    • Year: 2022
Phytochemical analysis and purification of chief components of Ononis spinosa
    • Authors: N. Fayyazi, F. Naghibi, S. Taheri
    • Journal: N/A
    • Year: 2014
A new insight into the mechanism of loading of Granisetron, Naltrexone and Risperidone in poly (ortho ester) and poly (lactic-co-glycolic acid) as the controlled release drug
    • Authors: L. Karami, N. Fayyazi, M. Akbari, A. Molaei-Baghbanan, M. Maaza
    • Journal: Journal of Drug Delivery Science and Technology
    • Year: 2024

Bohong Chen | Bioinformatics analysis | Best Researcher Award

Posted on by ScienceFather

Mr. Bohong Chen | Bioinformatics analysis | Best Researcher Award

Mr. Bohong Chen at The First Affiliated Hospital of Xi’an Jiaotong University, China

👨‍🎓Professional Profile

🧑‍🔬 Summary

Mr. Bohong Chen is a talented researcher from The First Affiliated Hospital of Xi’an Jiaotong University, China, currently pursuing his PhD with a focus on tumor drug resistance mechanisms, specifically for breast cancer. His work integrates transcriptomics, single-cell bioinformatics, and Mendelian randomization to better understand the molecular foundations of disease. With a strong academic background and multiple published articles in high-impact journals, Mr. Chen is well-equipped to contribute to foundational biomedical research aimed at improving cancer treatment strategies.

👨‍🎓 Education

Mr. Bohong Chen is currently pursuing a PhD at The First Affiliated Hospital of Xi’an Jiaotong University in China, where he focuses on exploring the mechanisms of tumor drug resistance, particularly for breast cancer. Prior to this, he earned his Master’s degree under the supervision of Wu Dapeng, equipping him with strong research skills in bioinformatics and molecular biology.

🏆 Academic Honors

Mr. Chen has received several prestigious academic honors, including a Second-Class Scholarship for two consecutive years and the title of “Excellent Graduate Student” for the 2021 academic year. Additionally, he serves as a reviewer for the SCI journal PLOS ONE, demonstrating his academic contributions.

💻 Technical Skills

With expertise in bioinformatics, Mr. Chen is proficient in using R Language for transcriptomic and single-cell data analysis. His skills also include Mendelian randomization, a method he uses for genetic epidemiology and to explore causal relationships in disease mechanisms. These technical skills form the backbone of his innovative research in tumor drug resistance and other medical conditions.

👨‍🏫 Teaching Experience

In addition to his research, Mr. Chen has demonstrated teaching abilities as a Master’s Supervisor under Wu Dapeng. He assists graduate students in their research and offers valuable guidance in bioinformatics and genomics.

🔬 Research Interests

Mr. Chen’s research interests are primarily focused on understanding tumor drug resistance, especially in breast cancer. He is particularly interested in leveraging advanced bioinformatics techniques such as single-cell sequencing and machine learning to identify novel therapeutic targets. His goal is to provide more effective treatment strategies for cancer patients by exploring the molecular mechanisms behind drug resistance.